Outcomes of Interferon-free Treatment of Hepatitis C Virus Infection Seven Years after Approval and Problems with Drop out during and after Treatment: A Retrospective, Single-center Study-Reference-Cited by-同舟云学术

Outcomes of Interferon-free Treatment of Hepatitis C Virus Infection Seven Years after Approval and Problems with Drop out during and after Treatment: A Retrospective, Single-center Study

Published:2022-10-15 Issue:20 Volume:61 Page:3017-3028
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Watanabe Masaaki¹,Yokomori Hiroaki²,Kitahara Gen¹,Uehara Kazuho¹,Koyama Shiori¹,Minamino Tsutomu¹,Otsuka Toshikazu¹,Kaneko Toru¹,Tahara Kumiko¹,Kida Mitsuhiro¹

Affiliation:

1. Department of Gastroenterology, Kitasato University Medical Center, Japan

2. Department of General Internal Medicine, Kitasato University Medical Center, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/61/20/61_0036-22/_pdf

Reference35 articles.

1. 1. Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol 12: 361-373, 2021.

2. 2. Enomoto H, Ueno Y, Hiasa Y, et al. The transition in the etiologies of hepatocellular carcinoma complicated liver cirrhosis in a nationwide survey of Japan. J Gastroenterol 56: 158-167, 2021.

3. 3. Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res 49: 1109-1113, 2019.

4. 4. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59: 2083-2091, 2014.

5. 5. Tahata Y, Sakamori R, Takehara T. Treatment progress and expansion in Japan: from interferon to direct-acting antiviral. Glob Health Med 3: 321-334, 2021.